Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm Exam 1 > Lash - Hematopoiesis > Flashcards

Lash - Hematopoiesis Flashcards

1
Q

INTRODUCTION:
• General:

A
  • Various drugs, hormonal growth factors, vitamins and minerals can affect the blood or blood-forming organs
  • Blood cells have relatively short life-spans, so you need continuous replacement of cells by hematopoiesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anemia:

A
  • Significant reduction in functional red cells mass with consequent reduction in O2 carrying capacity
  • Causes include:
    o Blood loss
    o Reduced red cell production
    o Production of abnormal red cells or precursors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Process of Hematopoiesis:

Pluripotent Stem Cell –>

Lymphocyte progenitor –>

CFU-GEMM –>

CFU-GM –>

A

Pluripotent Stem Cell –> Variety of different precursor cells

Lymphocyte progenitor –> B cells, T cells, NK cells

CFU-GEMM –>CFU-E/BFU-E and CFU-GM
–>CFU-E/BFU-E –> RBCs

CFU-GM –>Granulocytes (PMNs, Eosinophils, Basophils) and Monocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Erythropoietin:

Synthesis

Function

Absence

A

Synthesis:
o Proximal tubular cells of the kidney (primarily)
o Liver (small amount)
- Structure:
o Primary gene product 193 amino acid protein
o First 27 residues cleave during secretion
o Glycosylated (not essential for function but prolongs half-life)

Function:
o Most important regulator of:
Proliferation of committed progenitors (CFU-E)
Maturation of erythroblasts

Release of reticulocytes into circulation

Synergy with IL-3 and GM-CSF to expand BFU-E population
BFU-E mature to CFU-E, which then mature further into reticulocytes (released)

Acts by binding specific membrane receptors on the surface of bone marrow cells that are committed towards synthesis of RBCs

Absence: invariably results in anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diseases/Agents Affecting Production of Erythropoietin:
In General:

A

Anemia or hypoxia cause a RAPID increase (~100 fold) in the renal synthesis and secretion of erythropoietin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Disease State

Increase EPO (Kindeys, liver, brain, lung)

Decrease EPO

A

Increase EPO Production

  • Kidney (HTN, carcinoma, sarcoma, renal artery stenosis etc.)
  • Liver (carcinoma)
  • Brain (hemangioblastoma)
  • Lung (pulmonary insufficiency, emphysema, carcinoma, fibrosis)

Decrease EPO Production

–

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pharm agents that increases EPO

A
  • Cobalt (↓ tissue O2 use)
  • Thyroxine
  • Growth Hormone
  • Prolactin
  • ACTH (decreases renal blood flow)
  • Serotonin
  • Vasopressin
  • Testosterone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pharm agents that decrease EPO

A
  • Mercurial diuretics
  • Estrogens
  • Beta2 blockers
  • Adenosine A1 agonist
  • Calcium ionophores
  • Ca++ channel blockers (chronic use)
  • Phorbol esters
  • Alkylating agents
  • Diacylglycerol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

EPO Signaling Pathways that Regulate Expression:

Hypoxia

Detection

What changes after detection?

A

Hypoxia (due to anemia, ischemia, cobalt etc.) is detected by either:

  • Oxygen sensing cell
  • EPO producing cell itself

Detection occurs by changes in signaling molecules (ie. adenosine, prostaglandins etc.)

Once cell detects hypoxia, change in the cAMP pathway results in the activation of various proteins that stimulate the production and secretion of EPO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Myeloid (CSFs):

General:

Synthesis

A

General

Glycoproteins that stimulate proliferation and differentiation of several types of hematopoietic precursor cells AND enhance function of mature leukocytes

Synthesis:

o GM-CSF and IL-3: T lymphocytes
o GM-CSF, G-CSF and M-CSF: monocytes, fibroblasts, endothelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Function of Interleukin-3 (IL-3): (4)

A

Stimulates colony formation of most cell lines

Synergy with GM-CSF to increase number of PMNs, monocytes and eosinophils in the blood

Synergy with EPO to expand BFU-E compartment to stimulate CFU-E proliferation

Influences the function of eosinophils and basophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Function of Granulocyte/Macrophage CSF (GM-CSF): (5)

A

Synergy with IL-3 to stimulate colony formation/proliferation of granulocytes, monocytes/macrophages, and megakaryocytes

Synergy with EPO to promote formation of BFU-E

Increases phagocytic and cytotoxic potential of mature granulocytes

Reduces motility and clearance from circulation of mature granulocytes

Increases cytotoxicity of eosinophils and leukotriene synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Function of Granulocyte CSF (G-CSF): (5)

A

Stimulates granulocyte colony formation and production of PMNs

Synergy with GM-CSF to stimulate granulocyte/macrophage colonies

Synergy with IL-3 to induce formation of IL-3

Induces release of granulocytes from marrow

Increases phagocytic and cytotoxic potential of mature granulocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Function of Macrophage CSF (M-CSF/CSF-1):

A

Stimulates monocyte/macrophage colony formation (both alone and in synergy with GM-CSF and IL-3)

Induces synthesis of G-CSF and IL-1

Enhances production of IFN and TNF

Enhances functions of monocytes and macrophages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

EPO

Therapeutic Use

Administration

Pharmacokinetics

Toxicity

A

Therapeutic Uses:
Treatment of anemia resulting from chronic renal failure

Transfusion-dependent patients undergoing hemodialysis

Alleviated requirement for transfusions after several weeks

Eventually normalized hematocrit

Also corrects anemia in patients who do not require dialysis

o Treatment of anemia associated with AIDS patients of AZT

o Treatment of anemia associated with cancer chemotherapy

o Preoperative increase in red cell production to allow storage of larger volumes of blood for autologous transfusion

Administration:
 o Parenterally (IV or SubQ)

Pharmacokinetics:
o Need to titrate dose
 Avoid rapid increase in hematocrit early in therapy
 Avoid a rise in hematocrit to >36% during maintenance therapy
o Proper response to EPO requires adequate iron stores
 May need to co-administer oral iron supplement in those with iron deficiency

Toxicities and Side Effects:

o Increase in red cell mass (most common)
 Associated with HTN and thrombotic phenomena
 Minimized by raisin hematocrit slowly (titrating dose; monitor BP closely)
o Allergic responses infrequent and mild

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Myeloid Growth Factors (CSFs):
- Therapeutic Uses:

Stimulation of hematopoiesis in primary bone marrow failure: (3)

A

Correction of insufficient Hematopoiesis:
Anemia
Prevention of chemotherapy induced neutropenia
Possibility of dose intensification of chemotherapy
 Autologous bone marrow transplant

Stimulation of hematopoiesis in primary bone marrow failure:

Aplastic anemia
Congenital neutropenia
Idiopathic cytopenias

17
Q

CSF use in:

Treatment of leukemias (types)

Expansion and recruitment of circulating progenitor cells:

Activation of effector cell function (4)

A

o Treatment of leukemias:
 AML
Myelodysplastic syndromes

Expansion and recruitment of circulating progenitor cells:
Peripheral blood stem cell transplantation

Activation of effector cell function:
Infections
Leukocyte function disorders
AIDS
Tumor cytotoxicity

18
Q

Treatment of sickle cell

A

Treatment:

• Supportive treatment includes analgesics, antibiotics, pneumococcal vaccination, and
blood transfusions.
• The cancer chemotherapeutic drug hydroxyurea (hydroxycarbamide) reduces venoocclusive
events. It is approved in the United States for treatment of adults with recurrent
sickle cell crises and approved in Europe in adults and children with recurrent vasoocclusive
events.
• In the treatment of sickle cell disease, hydroxyurea acts through poorly defined pathways
to increase the production of fetal hemoglobin (HbF), which interferes with the
polymerization of HbS.
• Clinical trials have shown that hydroxyurea decreases painful crises in adults and
children with severe sickle cell disease.
• Adverse effects include: hematopoietic depression, gastrointestinal effects, and
teratogenicity in pregnant women.
Page

19
Q

• Myeloid Growth Factors (CSFs):

Toxicities and side effects:

Common?

Dose-limiting side effects of GM-CSF include:

Less side effects with G-CSF:

By themselves, growth factor:

A

Toxicities:

Relatively common with GM-CSF (dose-dependent):

Local induration after SC injection

Thrombophlebitis at site of infusion

Fever

Myalgias

Fatigue

Skin rashs

GI distress

Bone pain

Dose-limiting side effects of GM-CSF include:
Pericarditis
Pleuritis
Pleural effusions
Pulmonary emboli

Less side effects with G-CSF:
Bone pain
Vasculitis
Worsening of psoriasis

By themselves, growth factor may have oncogenic potential!

20
Q

IRON DEFICIENCY:

Basics:

Causes:

Consequences:

What else does iron deficiency affect?

Diagnosis: presence of or?

A

Basics: most common cause of nutritional anemia in humans

Causes:

  • Dietary intake of iron not adequate
  • Blood loss (GI tract, menstruation; most common cause in the US)
  • Some interference with iron absorption

Consequences:

  • Severe Cases: microcytic hypochromic anemia secondary to reduced synthesis of Hb
  • Does not only affect RBCs: alters muscle metabolism INDEPENDENT of effect on O2 delivery via blood

• Diagnosis:
- Presence of microcytic anemia, OR
- Quantitation of:
o Transferrin saturation
o Red cell protoporphyrin
o Plasma ferritin content

21
Q

Iron Stores in the Body:

Two Forms:

Gender Differences:

Location:

A

Iron Stores in the Body:

Two Forms:

Essential iron-containing compounds
 Excess iron (storage form)

Gender Differences: males have higher stores/kg of body mass than females

Locations of Iron Sources:
 Most: Hb in RBCs
 The Rest:
 Myoglobin in muscle
 Storage form bound to ferritin
 Cytochromes and other iron-containing enzymes (trace amounts)
 Transport form bound to transferrin

22
Q

Ferritin: protein of iron storage

Apoferritin:

Hemosiderin:

Locations:

A

Apoferritin: not bound to iron; composed of 24 polypeptide chains that form an outer shell with a storage cavity for iron inside (can bind up to 4000 atoms of Fe)

Hemosiderin: aggregated ferritin

Location: predominantly in reticuloendothelial system and liver; small amount in muscle

23
Q

Transferrin:

Function

A

Plasma glycoprotein for iron transport

Internal exchange of iron: has 2 binding sites for ferric ion; delivers iron to intracellular sites by binding specific transferrin receptors on cellular plasma membranes.

Iron is delivered from transferrin to intracellular sites by specific transferrin receptors

24
Q

Synthesis of Ferritin/Trasnferrin Receptors in Response to Iron Supply:

Excess Iron:

Low Iron:

A

Excess Iron: reduce synthesis of transferrin R; increased synthesis of ferritin

Low Iron: increased expression of transferrin R; decreased synthesis of ferritin

25
Q

Iron Requirements and Dietary Availability:

Varies by:

High iron foods:

Low iron foods:

Bioavailability of iron:

Absorption of non-heme iron facilitated by:

Form complex with:

A

Varies by age, gender and other factors:
o Highest for pregnant women (up to 4x increase in daily requirement)
o Menstruating females (blood loss) and infants (rapid growth) also have high requirements

High Iron Foods: organ meats, brewer’s yeast, wheat germ, egg yolks, oysters, some dried beans and fruits

Low Iron Foods: milk products, non-green vegetables

Bioavailability of Iron:
o Heme Iron: most bioavailable form, but dietary iron is mostly non-heme iron
o Absorption of Non-Heme Iron: facilitated by ascorbate
Forms complex with iron, OR
Reduces ferric –> ferrous iron

26
Q

Treatment of Iron Deficiency:

Oral Therapy:

Duration:

Adverse effects:

Overcome by:

A

Ferrous Sulfate: treatment of choice (~25% of oral iron given in this form is absorbed)

Duration: usually 3-6 months

Adverse Effects: nausea, epigastric discomfort, abdominal cramps, constipation, diarrhea

  • Dose-related
  • Overcome by lowering dose or taking tablets with meals
27
Q

Treatment of iron deficiency

Parenteral Thearpy:

Who?

Compare to oral:

A

Use:
Patients who can’t tolerate or absorb oral iron

Patients with chronic blood loss

Repletion of iron stores: more rapid than by oral therapy

28
Q

Interrelationship Between Vitamin B12 and Folic Acid:

Methionine Synthesis:

Purine Synthesis:

DNa synthesis:

Deficiency of either B12 or folate:

A

Methionine Synthesis: MeFH4 + B12  methylcobalamin, which then acts as methyl donor produce methionine

Purine Synthesis: requires folate derivatives

DNA Synthesis: requires folate derivatives to methylate dUMP  dTMP (required precursor)

Deficiency of Either B12 or Folate:
o Decreased synthesis of methionine and S-adenosylmethionine
o Interference with protein synthesis
o Interference with numerous methylation reactions
o Redirection of methylation reactions away from nucleic acid synthesis (compromises production of new cells)

29
Q

Vitamin B12

Metabolism:

Combines with:

Excess stored in:

Sources:

Daily Requirment:

A

Metabolism:
o Combines with intrinsic factor in stomach and duodenum (secreted by parietal cells of gastric mucosa)
o Requires IF for absorption in the distal ileum (specific receptor-mediated transport)
o Once absorbed, transported to cells of the body bound to plasma glycoprotein (transcobalamin II)
o Excess stored in the liver or excreted in the urine

Sources:
o Cannot be synthesized so needs to be obtained in the diet
o Only original source in nature is microorganisms
o Animal liver is excellent source (primary storage site)

Daily Requirements:
o Small daily requirement
o Daily turnover of liver vitamin B12 is small and therefore deficiency would not develop for 3-4 years

30
Q

B12 Deficiency

Affects what systems?

DNA effects

Most profound effects on what type of cell?

Most due to:

A
  • Deficiency
    o Affects both hematopoietic AND nervous systems:
     Sensitivity of hematopoietic system relates to high rate of cell turnover (requires high rates of DNA synthesis)

 Not enough B12 leads to highly abnormal DNA synthesis
 Results in morphologically abnormal cells or cells that die during maturation

 Most profound effect on RBCs (abnormally large)- megaloblastic anemia

o Nutritional B12 deficiencies are rare:
 Most due to malabsorption (NOT insufficient intake)
 Deficiency in IF (pernicious anemia, gastrectomy)
 Defects in absorption of B12-IF complex by distal ileum

31
Q

B12 Deficiency

Diagnosis

Treatment

A
  • Diagnosis:
    o Measurement of B12 in the serum
    o Measurement of methylmalonic acid in the serum
  • Treatment:
    o Most are not curable: require lifelong treatment with B12 injections (important to diagnose underlying cause so proper treatment can occur)
32
Q

Folic Acid:

Metabolism: absorption (requires) and transport (as)

Sources:

Deficiency:

Therapy:

A

• Folic Acid:

  • Metabolism:
    o Taken in via the diet: as reduced polyglutamates
     Absorption:
     Requires transport and a pteroyl-γ-glutamyl carboxypeptidase associated with the intestinal mucosal membrane
     Most occurs in duodenum and upper jejunum (have high activities of dihydrofolate reductase and methylating activities)
     Transport to Tissues:
     Mostly transported to tissues as MeFH4
     Bind plasma proteins
     Taken up into cells by receptor-mediated endocytosis
  • Sources:
    o Diet: almost all foods rich in folate (especially leafy green vegetables, liver, yeast, some fruit)
     Important point: cooking can destroy most of the folate content of these foods
  • Daily Requirements:
    o Most people take in much more folate than the minimum daily requirement
  • Deficiency:
    o Often caused by inadequate dietary intake:
     Elderly or the poor (lack vegetables, eggs, meat in diet)
     Prolonged cooking of folate rich foods
     Alcoholics and patients with liver disease (poor diet and diminished capacity of the liver to store folates)
    o Also causes megaloblastic anemia: difficult to distinguish from B12 deficiency

-Therapy:
o Diagnosis important: potential for mistreating patients with B12 deficiency with folates
 Will relieve megaloblastic anemia but will NOT help the neurological defects seen due to B12 deficiency

33
Q

Cobalt

Deficiency:

Historical Significance:

A

Deficiency: has not been reported in man

Historical Significance: used to be administered to treat anemia
o No benefit and aplastic anemia
o Beneficial to patients with pure red-cell aplasia (inhibition of enzymes in oxidative metabolism  tissue hypoxia  increase in secretion of EPO)
o Note: large amounts of Co DEPRESS erythropoiesis
 Intoxication in children can cause cyanosis, coma and death

34
Q

Pyridoxine (Vitamin B6):

Oral Therapy effects:

Anemia is characterized by:

Therapy effective for anemia due to certain drugs:

A

• Pyridoxine (Vitamin B6):

Oral Therapy: can increase hematopoiesis in patients with hereditary or acquired sideroblastic anemia

Anemia characterized by impaired Hb synthesis and accumulation of Fe in mitochondria of erythroid precurosor cells
 Hereditary form is X-linked recessive with variable penetrance and expression
 Idiopathic forms associated with use of certain drugs, inflammatory states, neoplastic disorders and preleukemic syndromes

Therapy effective for anemia due to certain drugs (isoniazid, pyrazinamide) but not for others
 May interfere with beneficial action of other drugs causing the anemia

35
Q

Riboflavin:

Deficiency

Therapy with is beneficial to:

A

Riboflavin:

Deficiency:
o Spontaneous red-cell aplasia (rare)
o Induced hypoproliferative anemia

Therapy with Riboflavin:
o Beneficial to patients with red-cell aplasia due to protein depletion

Pharm Exam 1 (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions